公开(公告)号：US20240271223A1

公开(公告)日：2024-08-15

申请号：US18569317

申请日：2022-04-07

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Megumi KURONISHI ,  Yu Kato

IPC: C12Q1/6886 ,  A61K31/47 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/47 ,  A61P35/00 ,  G01N2800/52

Abstract: Biomarkers are provided that predict whether a human subject having a tumor is in need of a therapy comprising an angiogenesis inhibitor (e.g. lenvatinib or a pharmaceutically acceptable salt thereof, such as lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having a tumor.